You just read:

Bridge Biotherapeutics Presents Positive Results from Phase 1 Clinical Study of BBT-877 for Idiopathic Pulmonary Fibrosis (IPF) Treatments at the ERS International Congress 2019

News provided by

Bridge Biotherapeutics, Inc.

Sep 29, 2019, 18:00 ET